Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
Schedule
Product: Rapamune
Active Ingredient: Sirolimus 2mg
Dosage Form: Coated tablet
New Zealand Sponsor: Pfizer New Zealand Limited
Manufacturers: Wyeth Pharmaceutical Company, Guayama, Puerto Rico
Wyeth Pharmaceuticals Inc, New York, United States of America
Note: This renewed consent is valid for two years from 12 January 2012.
Dated this 5th day of December 2011.
DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).